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Abstract
Given the almost limitless variety of nanomaterials, it will be virtually impossible to assess the 
possible occupational health hazard of each nanomaterial individually. The development of 
science-based hazard and risk categories for nanomaterials is needed for decision-making about 
exposure control practices in the workplace. A possible strategy would be to select representative 
(benchmark) materials from various mode of action (MOA) classes, evaluate the hazard and 
develop risk estimates, and then apply a systematic comparison of new nanomaterials with the 
benchmark materials in the same MOA class. Poorly soluble particles are used here as an example 
to illustrate quantitative risk assessment methods for possible benchmark particles and 
occupational exposure control groups, given mode of action and relative toxicity. Linking such 
benchmark particles to specific exposure control bands would facilitate the translation of health 
hazard and quantitative risk information to the development of effective exposure control practices 
in the workplace. A key challenge is obtaining sufficient dose–response data, based on standard 
testing, to systematically evaluate the nanomaterials’ physical–chemical factors influencing their 
biological activity. Categorization processes involve both science-based analyses and default 
assumptions in the absence of substance-specific information. Utilizing data and information from 
related materials may facilitate initial determinations of exposure control systems for 
nanomaterials.
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Introduction
Due to the vast number of chemical and physical agents in the workplace without 
occupational exposure limits (OELs), there is a critical need to develop health-based criteria 
for the selection and evaluation of exposure controls. New substances such as nanomaterials 
typically have limited health hazard data from which to evaluate the workplace exposure 
control needs. Yet, nanomaterials in several major categories (e.g., carbon-based, metals, 
metal oxides) are currently in production and use, and wide variations exist in the properties 
of specific materials within these major categories (e.g., differences in shape, size, surface 
functionalization) which may affect biological activity of these materials, for example, if 
inhaled by a worker.
Trends in nanotechnology are moving from research and development toward 
manufacturing with a currently small, but growing, segment of the work-force (Invernizzi 
2011). With the increased manufacturing of nanomaterials and nanomaterial-containing 
products comes the potential for occupational exposure to these materials during their 
production or use. Information is needed to make informed decisions about the level of 
exposure control needed to protect workers’ health. In general, the less that is known about a 
substance, the greater should be the precaution in selecting the level of exposure control 
(Schulte and Salamanca-Buentello 2007). In the absence of OELs for most nanomaterials, 
hazard and control banding approaches have been proposed, but these processes generally 
have not been validated concerning the level of health protection afforded by those systems.
The purpose of this paper is to describe the concepts and challenges of using benchmark 
particles in developing hazard- and risk-based categories for nanomaterials’ OELs. A 
benchmark particle is essentially a reference material which has been tested and evaluated 
according to standard criteria and to which new materials may reliably be compared. An 
example is provided in this paper of quantitative risk estimation and the comparative 
potency of various types of poorly soluble respirable particles (PSP), and one type of soluble 
particle, associated with lung cancer in rat chronic inhalation studies. These data were 
selected because PSP are an example of a possible mode of action (MOA) category due to 
their potential to cause chronic adverse lung effects related to their biopersistence in the 
lungs. The rat is a sensitive rodent species for adverse lung effects including persistent 
pulmonary inflammation and lung cancer associated with exposure to respirable PSP 
(Mauderly 1997; NIOSH 2011). Chronic health effects data are particularly needed in 
current hazard and control banding schemes.
With the growing variety of nanomaterials, there will be a greater need to identify the level 
of exposure control and containment needed for various types of nanomaterials. Developing 
a set of benchmark particles with a full quantitative risk assessment, and utilizing validated 
shorter-term studies to compare the nature and severity of response in standard assays, could 
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increase the efficiency of OEL development and exposure controls for nanomaterials. 
Despite the large variation in nanomaterials, the exposure control options are much fewer, 
and may be defined within relatively few bands (e.g., order of magnitude) (Naumann et al. 
1996; Ader et al. 2005; Hewett et al. 2006). Controlling exposures is the most important step 
in preventing occupational lung disease in workers.
An OEL strategy for nanomaterials
The process of evaluating health effects data for development of OELs can be viewed as 
three branches depending on the amount of available scientific evidence (Schulte et al. 
2010): (1) Adequate (sufficient) dose–response data for quantitative risk assessment (QRA) 
and OEL development; (2) Suggestive (insufficient) data for QRA on the substance of 
interest, but adequate information on another substance with similar physical–chemical 
properties and likely biological mode of action; and (3) Minimal (limited) data on which to 
make a quantitative comparison so hazard and control bands are inferred by analogy to a 
similar type or class of materials (Fig. 1).
This strategy provides a systematic approach to developing health-based exposure controls 
for nanomaterials including those with suggestive or minimal data. The key to this approach 
is the identification of relevant benchmark (reference) particles, which can be defined as 
substances with adequate data on dose–response relationships and biological MOA for use 
in quantitative risk estimation and derivation of health-based OELs. Developing OELs for 
representative benchmark particles within each of these MOA categories (Table 1) would 
provide a basis for linking the health effects data to the exposure controls for nanomaterials 
with limited data. Using the example of control banding systems developed for 
pharmaceuticals and other types of dry powders, order of magnitude bins might be used as 
the first level of default categories (Fig. 2) with more narrow bands or specific OELs 
developed as data become available.
Categorical approaches
Several qualitative hazard-based categories and control banding schemes have been 
developed for hazardous substances in the workplace including nanomaterials. These 
include: relative hazard and risk ranking frameworks for nanomaterials (Linkov et al. 2007, 
2009; Tervonen et al. 2009; Grieger et al. 2012), nanomaterial-specific control banding 
schemes (Zalk et al. 2009; ANSES 2010), and the United Nations’ globally harmonized 
system of classification and labelling of chemicals which was recently adopted in the U.S. 
(77 FR 17574, March 26, 2012). However, absolute risk estimates or risk-based OELs for 
reference or benchmark materials within these categories are needed to link the hazard and 
relative risk information to the level of exposure control needed to protect workers (e.g., at a 
minimum, order of magnitude bands, Naumann et al. 1996; Ader et al. 2005).
The concept of developing benchmark materials for hazard and risk assessment of 
nanomaterials, including by utilizing data from existing studies in humans and animals of 
exposure to inhaled particles and fibers, was proposed earlier (Kuempel et al. 2006, 2007). 
Since that time, additional toxicology data have become available for some nanomaterials 
and categorical approaches have become more widely recognized or adopted (BSI 2007; 
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OECD 2007; NIOSH 2010a, b; Schulte et al. 2010)—providing greater opportunity and 
need to quantitatively evaluate these approaches. Yet, health effects data on most 
nanomaterials are still lacking. In the absence of nanomaterial-specific data, initial estimates 
of OELs for nanomaterials could be developed by adjusting the OELs for benchmark 
particles (e.g., larger particle size material of the same chemical composition) by the 
differences in the surface area, surface reactivity, and other factors that are associated with 
the adverse effect (Kuempel et al. 2007). However, OELs can vary widely with regard to the 
hazards and risks associated with exposure (e.g., due to differences in the derivation 
methods and technical feasibility of measuring and controlling exposure) and so do not 
provide a standard health basis for comparison. Thus, a quantitative comparison of 
nanoparticle toxicity to benchmark particles (including consideration of the role physical–
chemical properties) was suggested as a preferable method if sufficient data were available 
(Kuempel et al. 2007). An example of a comparative toxicity approach (Schoeny and 
Margosches 1989) utilizes the “parallelogram” extrapolation method (Sobels 1993). These 
comparative toxicity analyses could be conducted in short-term assays for a set of 
nanomaterials in which the benchmark particles are the reference particles (e.g., positive and 
negative controls) to which the new materials would be compared (Fig. 3).
In an early example of categorical exposure limits, the British Standards Institute (BSI 2007) 
proposed setting “benchmark exposure limits” or “BELs” for nanomaterials based on 
analogy to substances in four main categories including (1) fibers; (2) carcinogenic, 
mutagenic, asthmatic, or reproductive toxicants; (3) insoluble; and (4) soluble substances 
(BSI 2007). BELs for nanomaterials were proposed at one-half to one-fifteenth of the OEL 
for the larger particles or fibers of similar chemical composition or structure (e.g., based on 
particle surface area of insoluble particles as in the 2005 NIOSH draft TiO2 recommended 
exposure limits (NIOSH 2011), or by means of uncertainty factor adjustments (BSI 2007)).
Within three broad categories (carcinogenic, high toxicity, low toxicity), Dolan et al. (2005) 
proposed a method to derive exposure limits (acceptable daily intake, ADI) for new 
substances with minimal data. The ADI for a new substance would be set at the 5th 
percentile of the ADIs for all nongenotoxic substances based on the assumption that a 
relatively unstudied compound would be unlikely to have a lower ADI once its true potency 
is determined (Dolan et al. 2005). A refinement of such methods, as discussed in this paper, 
would be to further develop the MOA categories and the hazard predictors (e.g., specific 
physical–chemical properties) in order to obtain better estimates of the actual hazard and 
risk of a nanomaterial.
Role of physical–chemical properties
The physical–chemical properties of particles and fibers, including nanomaterials, can 
influence the internal dose and the biological response to those materials through different 
modes of action (Table 1). Such properties include solubility, surface area, surface 
reactivity, size, and shape (Maynard and Kuempel 2005; Oberdörster et al. 2005a, b; 
Donaldson et al. 2010; Castranova 2000, 2011; Zhang et al. 2012). The size and shape of 
airborne structures influence their inhalability as well as deposition efficiency within the 
respiratory tract regions. As the airborne particle size decreases into the nanoparticle size 
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range (<100 nm), the fraction of inhaled particles that deposit in the alveolar (gas-exchange) 
region of the lungs generally increases (up to ~50 %) (ICRP 1994; Maynard and Kuempel 
2005). The dose metrics of mass, volume, number, or surface area of particles or fibers 
retained in the lungs have been associated with lung responses to inhaled particles or fibers 
in rats and mice (Morrow 1988; Oberdörster and Yu 1990; Muhle et al. 1991; Oberdörster et 
al. 1994; Tran et al. 2000; Elder et al. 2005; Nakanishi 2011; Pauluhn 2011; Murray et al. 
2012). Working lifetime exposures to respirable particle mass and fiber number 
concentrations have been associated with nonmalignant and malignant lung diseases in 
workers (reviewed in: Kuempel and Maynard 2005; Oberdörster et al. 2005b; Rom and 
Markowitz 2006). In a recently published study, airborne exposure to the nanoscale diesel 
exhaust particulate (DEP) was associated with lung cancer in miners (Attfield et al. 2012). 
Cumulative exposure to the thinnest (<0.3 μm in diameter) and longest (>10 μm in length) 
structures of airborne chrysotile was the best predictor of asbestosis and lung cancer in 
textile workers (Stayner et al. 2008). Lung responses observed in both animals and humans, 
as reported in the studies cited above, include buildup and retention of particles or fibers in 
the lungs, pulmonary inflammation, fibrosis, and lung cancer.
The challenge remains to develop predictive models of the toxicity of nanoparticles based on 
their properties (e.g., quantitative structure activity relationships, QSAR). Thus, a basic set 
of data reported in all studies on particle characterization, dose metrics, and response 
measures would aid in the interpretation of findings across studies and facilitate the pooling 
of data. This would considerably increase the information base for comparing toxicity and 
estimating risk for individual nanomaterials or groups of nanomaterials. Benchmark 
particles would be included in the toxicity testing (e.g., as positive and negative control 
particles administered in the same test system as the nanomaterials) (Oberdörster et al. 
2005a) along with a standard set of physical–chemical properties reported in each study 
(Oberdörster et al. 2005a; Warheit et al. 2007). Standardizing a minimum set of dose metrics 
and biological endpoints of relevance to humans would facilitate comparison of toxicity 
across nanomaterials for risk assessment (Table 2).
Risk assessment framework
A hazard- and risk-based categorization approach to nanomaterials’ OELs, such as proposed 
in this paper, is consistent with the U.S. National Research Council (NRC) 
recommendations to increase the utility of risk assessment for risk management decision-
making (NRC 2009). In its revised guidelines, the NRC (2009) recommended first to 
evaluate the options to reduce the hazard or exposure and then to determine what risk 
analyses are needed to decide among these options. Starting with the options for exposure 
control (e.g., order of magnitude bins and associated performance-based engineering control 
systems as previously proposed) (Fig. 2) provides a framework to link the hazard and risk 
information more directly to the exposure control options. Research priorities would include 
those studies that provide information to reduce uncertainty in decision-making concerning 
the exposure control options.
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Example of quantitative risk assessment of poorly soluble particles
Methods
Standard quantitative risk assessment methods for inhaled particles including nanoparticles 
have been previously described (Kuempel et al. 2006). This general approach is applied here 
to evaluate the dose–response data from chronic inhalation studies in rats exposed to various 
types and sizes of airborne particles. Benchmark dose (BMD)1 methods (U.S. EPA 2010) 
were used to estimate human-equivalent working lifetime exposure concentrations 
associated with a 1/1000 (0.1 %) excess risk of lung cancer. This critical effect level was 
selected because the 1/1000 has been described a significant risk for a severe chronic health 
effect (leukemia in that case) (U.S. Supreme Court 1980). BMD methods have several 
advantages over other effect level estimates (e.g., no observed adverse effect level, NOAEL, 
or lowest observed adverse effect level, LOAEL) by providing a standardized, risk-based 
approach that uses all of the dose–response data and takes statistical account of the sample 
size and variability in the data.
The steps in this risk assessment approach include:
1. Identify the relevant animal model, dose metric, and disease response (in this 
example: rat, airborne particle exposure concentration or retained particle dose in 
the lungs, and lung cancer);
2. Model the animal dose–response relationship and estimate the critical effect level, 
BMD(L)2;
3. Extrapolate the animal critical effect level estimates to humans by adjusting for the 
factors that influence the deposited or retained lung dose in each species, assuming 
equal response at equivalent dose3;
4. Estimate the airborne exposure (8-h time-weighted average, TWA) that would 
result in the human-equivalent dose4;
The particles evaluated in this example are from chronic inhalation (2-year) bioassays of 
PSP in rats (NTP 1996–2000; Lee et al. 1985; Heinrich et al. 1995; Nikula et al. 1995). 
These studies were selected because they provide relevant toxicology data to identify 
chronic lung disease hazards and the doses associated with those effects. Data are presented 
for both fine and ultrafine (nanoscale) particles. The lung tumor responses include 
carcinoma and adenoma, but exclude squamous cell keratinizing cysts. No a priori 
1A benchmark dose (BMD) is the dose associated with a specified increase (e.g., 10 %) in the probability of a given response known 
as the benchmark response (BMR) (Crump 1984). The BMD is a maximum likelihood estimate, and the BMDL is the 95 % LCL of 
the BMD.
2A critical effect level of 0.1 % excess risk of lung cancer is estimated in this example by linear extrapolation of the 10 % BMD and 
BMDL estimates. The BMD(L) estimates are based on lung burden at the end of the two-yr exposure if those data were available or on 
airborne exposure concentration otherwise.
3For those particles with 2-yr rat lung burden data, the rat critical lung dose (as particle mass or surface area dose per g lung) was 
converted to mg/lung to use as the target lung dose in a human lung dosimetry model (assuming average worker lung weight of 1000 
g) (ICRP 1975) (CIIT and RIVM 2006). For those particles without 2-yr rat lung burden data, the deposited daily dose (mg/d) was 
calculated by accounting for the species differences in ventilation rates and alveolar deposition fractions (Kuempel et al. 2006).
4Human-equivalent 45-yr working lifetime concentrations were estimated in a human lung dosimetry model (CIIT and RIVM 2006) 
for those particles with rat lung burden data. For those particles without rat lung burden data, the human 8-hr TWA concentrations 
were estimated by adjusting for the species differences in the alveolar surface area (102 m2 human/0.4 m2 rat), particle size-specific 
deposition fraction, and ventilation (assuming reference worker rate of 9.6 m3/8-hr d) (ICRP 1994) (Kuempel et al. 2006).
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differences in lung tumor responses by gender were assumed, and male and female rat dose–
response data (if available in the same study) were first evaluated together. The multistage 
cancer model (polynomial degree 2) within the BMD software (U.S. EPA 2010) was 
selected in this analysis because it is a longstanding model in cancer risk assessment. When 
model fit to the data were not adequate (i.e., p < 0.05), data were evaluated separately by 
gender. In some cases, adequate dose–response was obtained for one gender only. When 
model fit to each was adequate, the lower BMD(L) estimates were selected for this analysis.
Results
Tables 3 and 4 provide estimates of the working lifetime exposure concentration associated 
with a 1/1,000 excess risk of lung cancer based on animal-to-human extrapolation of 
benchmark dose estimates from the NTP chronic inhalation studies in rats. Table 3 provides 
estimates based on the rat airborne exposure concentrations and Table 4 provides estimates 
for the subset of particles in Table 3 for which measured rat lung particle burden data were 
available at the end of the two-year exposure. Both maximum likelihood estimates (MLE) 
and 95 % lower confidence limit (LCL) estimates are provided. Within individual particle 
types, the MLE and LCL estimates are fairly similar, whereas there are clear differences in 
these estimates among particle types.
The working lifetime exposure concentration (8-h TWA) associated with 0.1 % excess risk 
of lung cancer based on rat chronic inhalation exposure data differs by approximately three 
orders of magnitude across the various particle types and sizes (Table 3). The lowest human-
equivalent airborne concentrations are estimated for nickel (NiO and Ni2S3),5 cobalt, and 
gallium arsenide, which are all fine-sized particles. Slightly higher human-equivalent 
airborne concentrations are estimated for the ultrafine particles (carbon black, CB, and 
DEP), while the highest airborne concentrations are estimated for fine-sized oxides of 
molybdenum and titanium. The working lifetime 8-h TWA concentration estimates are 
within a factor of two or three for those particles with both exposure concentration and 2-
year lung burden data (i.e., fine- sized TiO2 and, DEP, ultrafine CB) (Tables 3, 4).
By means of the 95 % LCL estimates of working lifetime exposure concentrations 
associated with 0.1 % excess risk of lung cancer, the various particles in these analyses 
(Tables 3, 4) can be ranked by potency as follows:
• Low [>1 mg/m3 bin] (1,000–4,000 μg/m3): fine TiO2 and MoO3 (fine-sized 
particles)
• Moderate [~0.1–1 mg/m3 bins] (~90–250 μg/m3): CB, DEP, and ultrafine TiO2 (all 
are ultrafine particles)
• High [0.01–0.1 mg/m3 bin] (20–30 μg/m3): NiO and CoSO4 (fine particles) 
(CoSO4 is soluble)
• Very high [0.001–0.01 mg/m3 bin] (4–5 μg/m3): Ni3S2 and GaAs (fine particles)
5The greater tumor potency of Ni3S2 compared to NiO may be due to oxidative DNA damage (8-OH-dG), which was observed in 
cultured cells treated with Ni3S2, but not in cells treated with NiO or NiSO4 (Kawanishi et al. 2002).
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Both order of magnitude bins (e.g., Fig. 2) and the more specific exposure concentration 
estimates Tables 3 and 4 are shown for these particles. The more potent and hazardous 
particles are those with the lower 8-h TWA concentration estimates associated 1/1,000 
excess risk of lung cancer over a 45 year working lifetime. Thus, these ultrafine 
(nanostructured) particles would not be the lowest health-based OEL group among these 
various types of respirable particles in this analysis.
Discussion of QRA example
These results show that even by means of standard risk assessment methods and rodent 
bioassay data, the risk-based estimates can vary depending on the models and methods used. 
In this example, estimates are generally within a factor of two–three based on either 
exposure concentration or retained lung burden (Tables 3, 4). The lung dose estimates 
(Table 4) would be expected to be more biologically based by accounting for the long-term 
clearance and retention of particles in the lungs.
Differences in the male and female rat dose–response relationships were observed for some 
particles. For CB and DEP, the tumor response in female rats (Nikula et al. 1995; Heinrich 
et al. 1995) (shown in Table 3) was higher than that in male rats (Nikula et al. 1995) based 
on the airborne exposure data (which resulted in ~5× higher estimates than those in Table 3). 
Based on the lung burden data for DEP (Table 4), the dose–response relationship was 
similar in male and female rats, which provided marginally adequate fit (p = 0.07) by 
combining these data (Nikula et al. 1995; Heinrich et al. 1995). Similar MLE (95 % LCL) 
estimates of 0.24 (0.22) to those in Table 4 were obtained for the female data only (Nikula et 
al. 1995; Heinrich et al. 1995) with better goodness of fit (p = 0.6). For NiO, the male rat 
exposure concentration data were also adequately fit by the multistage model (p = 0.1) and 
resulted in ~2× higher BMD(L) estimates compared to the female rats (p = 0.2). These data 
suggest that even without inclusion of the squamous cell keratinizing cystic tumors, there is 
some tendency for the female rats to be more sensitive to developing PSP exposure-related 
lung tumors. It may also be that some of the studies did not fully differentiate between the 
squamous cell carcinoma and the squamous cell keratinizing cystic tumors, which have been 
observed in higher proportions of female rats after chronic exposure to PSP (e.g., TiO2) 
(NIOSH 2011).
Some of these 8-h TWA concentration estimates are similar to current OELs, and others 
differ considerably. For example, the 95 % LCL estimates associated with the 1/1,000 
excess risk of lung cancer from working lifetime exposure to DEP (0.09–0.23 mg/m3, 8-h 
TWA) (Tables 3, 4) are similar to the current permissible exposure limit (PEL) for DEP in 
mines (0.16 mg/m3) (CFR 2001). However, the human databased lung cancer risk estimates 
associated with DEP exposure are generally higher than those based on the rat data, 
suggesting that the rat model may underpredict the human working lifetime lung cancer risk 
from DEP (Kuempel et al. 2009).
In contrast, the worker-equivalent airborne concentration estimates for ultrafine CB (i.e., 
0.10–0.12 mg/m3, 95 % LCL estimates, Tables 3 and 4) are considerably lower than the 
current NIOSH recommended exposure limit (REL) and the Occupational Safety and Health 
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Administration (OSHA) PEL (3.5 mg/m3; in addition, the NIOSH REL includes 0.1 
PAHs/m3) (NIOSH 2005). The estimates for ultrafine and fine TiO2 (Tables 3, 4) are similar 
to the NIOSH RELs (0.3 and 2.4 mg/m3, respectively) (NIOSH 2011), although different 
dose–response models were used to derive these estimates (i.e., a multistage model with 
linear low-dose extrapolation in this example for consistency across particles evaluated vs. a 
weighted average of three nonlinear models in NIOSH 2011). An earlier analysis of a subset 
of these data showed that the lung dosimetry model selection and the interspecies dose 
normalization assumptions also influence the quantitative risk estimates (Kuempel et al. 
2006), although the relative risk rankings of particles were consistent.
The derived OELs may also depend on the response endpoint. For example, the American 
Conference of Governmental Hygienists’ (ACGIH) threshold limit value (TLV) for GaAs of 
0.3 μg/m3 (ACGIH 2008) is based on pulmonary inflammation, which is lower than the 8-h 
TWA concentration of 4.3 μg/m3 (95 % LCL) estimated in this example to be associated 
with a 0.1 % excess risk of lung cancer (Table 3). [NIOSH and OSHA do not list OELs for 
GaAs]. In general, an earlier stage, more sensitive response (i.e., develops at lower 
exposures) would be expected to result in lower OELs than those based on later-stage, more 
severe responses.
Some comparative potency information for non-cancer lung responses (including pulmonary 
fibrosis) is provided in Table 5 for single- or multi-walled carbon nanotubes (SWCNT, 
MWCNT) and possible benchmark particles including ultrafine carbon black, crystalline 
silica, and asbestos. CNT was estimated to be from 1.5 to 10× more potent than ultrafine CB 
(Table 5). The factor of 10× is from a comparison of NOAELs, which may depend on the 
dose spacing across the studies versus the within-study comparisons for the other potency 
factor estimates. Since human studies have been published on pulmonary fibrosis and/or 
lung cancer responses from occupational exposure to these possible benchmark particles, 
these studies provide data to evaluate the concordance of animal- and human-based risk 
estimates, which can help to reduce the uncertainty in inter-species extrapolation (Kuempel 
et al. 2009).
Discussion and next steps
To deal with the large number of nanomaterials without OELs, categorization approaches 
have been proposed based on similar physical–chemical properties, biological mode of 
action, and comparative potency analyses (Kuempel et al. 2006, 2007; BSI 2007; OECD 
2007). Benefits of a categorization approach to developing OELs include: more efficient use 
of data, reduced costs and animal use, increased sample size, greater robustness of results, 
and increased biological plausibility for other materials in the same mode of action category 
(OECD 2007).
Benchmark particles are needed to link the hazard data to the level of exposure control 
needed to protect workers’ health as well as to provide a standard basis for developing OELs 
across substances (e.g., chronic inhalation hazards). The OEL for the benchmark particle 
would provide information about the health risk of a nanomaterial in the same mode of 
action category, either estimated directly or adjusted by the physical and chemical properties 
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that modify the potency (e.g., increased particle surface area, surface reactivity, or 
solubility). Characterizing the distribution of effect levels is an important component of 
developing MOA categories and could also be used to estimate an OEL for a new member 
to the group (e.g., Dolan et al. 2005). If the variability in potency within an MOA category 
is great (e.g., overlaps the exposure control options that would impact decision-making), this 
may indicate a biological or practical need to split the category into subcategories. 
Crystalline silica is an example of a substance that has qualitatively the same mode of action 
as other poorly soluble particles (i.e., generation of reactive oxygen species resulting in 
chronic pulmonary inflammation), but it is much more potent and causes pulmonary 
inflammation at a much lower dose than lower toxicity particles (e.g., titanium dioxide) 
(Maynard and Kuempel 2005; NIOSH 2011). Thus, crystalline silica may be a benchmark 
particle for the MOA category of poorly soluble particle with highly reactive surfaces. On 
the other hand, ultrafine TiO2, DEP, and CB are all PSP that give similar risk estimates for 
lung cancer in the rat model; that is, the working lifetime exposure concentrations associated 
with the 1/1,000 excess risk of lung cancer for these substances all fall within a fairly narrow 
range (~0.1–0.2 mg/m3 based on model estimates in Table 4). To be most health protective, 
OELs would be based on earlier stage, lower severity effects (e.g., inflammation) if the 
earlier effect is on the causal pathway between exposure and a chronic adverse health effect. 
In that case, prevention of the earlier effect would also be expected to reduce the probability 
of a more severe chronic effect.
Categorical OELs could be based on qualitative and/or quantitative comparisons with 
benchmark particles. Some of the MOAs and dose metrics for inhaled particles and fibers 
are likely to apply to nanomaterials. For example, the total surface area dose has been 
associated with adverse lung responses for various types and sizes of poorly soluble particles 
(Oberdörster and Yu 1990; Oberdörster et al. 1994, 2005b; Driscoll 1996; Tran et al. 2000) 
as well as various types of carbon nanotubes (Nakanishi 2011). In other cases, the reactivity 
of the surface (e.g., generation of reactive oxygen species) needs to be considered (Duffin et 
al. 2007; Rushton et al. 2010). Particle mass or volume dose has also been associated with 
the rat lung responses to poorly soluble low toxicity particles (Morrow 1988; Muhle et al. 
1991) including MWCNT (Pauluhn 2011). The number concentration of specific sized 
structures has been associated with the inflammatory effects of nanotubes and fibers 
(Donaldson et al. 2010). Finally, the solubility of nanoparticles may be increased compared 
to the same mass of larger particles due to the increased available surface of nanoparticles. 
Even poorly soluble particles may be sufficiently soluble in the acidic fluid inside lung 
alveolar macrophages to trigger a biological effect as has been shown for immune responses 
associated with chronic beryllium disease (Stefaniak et al. 2011). The range of possible dose 
metrics illustrates that toxicity studies need to provide sufficient particle characterization to 
convert among the various dose metrics, which would facilitate hypothesis testing and 
identification of the most predictive dose metric.
Not all poorly soluble inhaled particles may cause lung cancer in rats or mice through an 
inflammation mode of action, but they may be genotoxic by other mechanisms including 
direct DNA damage (Melnick et al. 2003). Some nanomaterials have been shown to disrupt 
normal cell processes including cell division (mitosis) resulting in genotoxicity including 
aneuploidy (abnormal chromosome number) (Sargent et al. 2009 2011). Some CNT can also 
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cause rapid development of pulmonary fibrosis by a different mechanism (i.e., acting as a 
lung basement membrane, encouraging lung fibroblast growth) (Wang et al. 2010). This 
suggests that standard toxicity tests based on inflammation may not detect the fibrotic 
hazard of CNTs. Alternative modes of action and relevant assays should also be evaluated to 
identify any critical effects beyond the lungs.
The array of candidate benchmark particles discussed in this paper could be expanded as 
additional dose–response data become available particularly in short-term or subchronic 
studies. For example, the OECD (2010a, b) list of nanomaterials currently undergoing 
standardized toxicity testing could be evaluated by means of comparative potency analyses 
when relevant benchmark particles are used as controls. As more systematic data are 
available, further development of QSAR-based predictive models may also be feasible to 
improve the throughput for hazard and risk estimation and exposure control decisions.
As a next step, we are compiling data of possible benchmark particles within these four (or 
more) MOA categories (Table 1). The analysis steps will include identification of the health 
endpoint(s) of concern, selection of relevant toxicology assay data, and evaluation of dose–
response relationships and effect levels for a range of nanoparticles and benchmark particles 
within MOA categories. A framework such as this provides a basis to develop an initial 
matrix of nanomaterial hazard- and risk-based exposure control bins, and to guide the testing 
needs to evaluate whether the initial estimates are reasonable.
As illustrated in this paper, even a relatively simple case involving “gold standard” animal 
bioassay data (chronic inhalation exposure of various types of fine and ultrafine particles) 
raises a number of questions concerning the implementation of standard response endpoints 
and risk assessment methods. One criterion for meaningful differences in the hazard/risk 
groups may be the extent to which different options are available for exposure control to 
those levels. Hazard-and risk-based categorical OELs are consistent with the concept of 
exposure control banding approaches and are useful in risk management decision-making 
(Fig. 2).
Benchmark particles could provide a quantitative link to the current hazard and control 
banding schemes that have qualitative descriptors of severity and likelihood of adverse 
effects (e.g., low to high severity, and unlikely to probable) (Maynard 2007; Schulte et al. 
2008; Zalk et al. 2009; ANSES 2010). Exposure control decisions are typically based on 
exposure frequency, amount used, and dustiness of material as well as the hazardous 
properties of the material. Benchmark particles could also provide risk estimates for 
calibration and validation of other nanomaterials’ risk analysis frameworks such as those 
based on multi-criteria decision analysis (MCDA) methods (Linkov et al. 2007, 2009; 
Grieger et al. 2012).
In any occupational exposure control strategy, including control banding, worker health 
protection is the primary concern. Thus, the upper limit of the bands should not be 
interpreted as the maximum permissible average exposure. Rather, exposures should be well 
controlled within that band based on the demonstrated performance of the applicable 
engineering control systems and statistical confidence in the sampling results including 
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accounting for variability in exposures. The target for designing a control system should be 
at the low end of the band, recognizing that there may be excursions, so that exposures are 
controlled within the band. If appropriate controls are installed and used properly, then 
exposure monitoring could be performed periodically to verify that the system is functioning 
as designed (including using surrogate substances to check for release if a nanomaterial-
specific method is not available). The technical feasibility of measuring or controlling 
exposures is a continuing challenge. Jones and Nicas (2006) reported that the margins of 
safety (MOS) (i.e., ratios of worker exposures/animal effect levels) were too low (<1–100) 
using the recommended exposure controls of COSSH Essentials and ILO control banding 
toolkits, whereas higher MOS factors would be more health protective given the uncertainty 
in exposure control estimates based on animal data. Benchmark particles could also be used 
for such evaluations.
In summary, a hazard- and risk-based categorical approach would have several benefits 
including:
• Employing standard tools and methods to develop initial OELs and exposure 
control bands (and to reassess as new data become available);
• Identifying the minimum data standards for harmonization across studies;
• Allowing for development of a database with standard parameters for use in pooled 
or comparative analyses;
• Providing a framework for testing and refining hypotheses;
• Facilitating the systematic evaluation to select—or design—safer nanomaterials.
A number of challenges also exist in developing a categorical approach to evaluating the 
health hazards and risks across the various nanomaterials. In particular, further development 
of predictive models is needed, including comparison of short-term to long-term in vivo 
responses, and multivariate models with parameters for the various physical–chemical 
properties. Some advances have been made in developing models and methods for in vitro to 
in vivo comparison of toxicity and potency across a range of particle types and sizes 
including nanoparticles (Donaldson et al. 2008; Rushton et al. 2010). Standard sets of 
particle descriptors, dose metrics, and response parameters (Tables 1 and 2) are also needed 
in order to compare mode of action and dose–response relationships across studies.
Conclusions
Given the many different types of nanoparticles, comprehensive data for quantitative risk 
assessment on each specific type of nanoparticles are not likely to be feasible. Toxicological 
studies suggest that current OELs developed for larger respirable particles may not be 
adequate to protect workers exposed to some nanoparticles over a working lifetime. As 
illustrated here, existing scientific literature on ultrafine and fine particles can be used to 
estimate workplace exposure concentrations and provide a set of possible benchmark or 
reference particles. Linkages between short-term and chronic responses and in vitro to short-
term in vivo responses are needed to increase testing efficiency of comparative toxicity 
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evaluations. Benchmark particles may also be used to calibrate and validate the various 
hazard and control banding schemes.
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Fig. 1. 
Possible strategy for developing exposure control limits and bands—incorporating risk-
based estimates from comparative potency to benchmark particles (well-characterized 
substances with health-based OELs). Figure adapted from Schulte et al. (2010)
Kuempel et al. Page 18
J Nanopart Res. Author manuscript; available in PMC 2015 October 24.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig. 2. 
Integrating risk assessment with hazard and exposure control banding—an example of order 
of magnitude bins. * 8-h time-weighted average concentration. Exposure control limit bands 
and engineering control systems based on: Naumann et al. (1996); Ader et al. (2005); Zalk 
and Nelson (2008)
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Fig. 3. 
Comparative potency and parallelogram approaches to risk estimation for new materials. 
(Based on concepts discussed in: Schoeny and Margosches 1989; Sobels 1993 (and earlier 
papers); Sutter 1995). The relative potency (described by k) between particle type 1 and 2 in 
a short-term assay, along with the relationship between short-term and long-term toxicity 
and risk for particle type 1, is used to estimate the risk of adverse health effects from long-
term exposure to particle type 2 (assuming the same relative potency, k’)
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Table 1
Possible group-specific categories and modes of action for nanoparticles related to hazard and risk assessment
Group-specific considerations Higher solubility particles Poorly soluble, low 
toxicity (PSLT) 
particles
Poorly soluble, 
high toxicity 
particles
Fibrous particles
Example benchmark particles Zinc oxide
Copper oxide (I)
Titanium dioxide
Carbon black
Crystalline silica
Nickel oxide (III)
Carbon nanotubes
Carbon nanofibers
Adverse effects Acute lung effects
Systemic toxicity
Lung inflammation 
and fibrosis; lung 
cancer (rats)
Chromiun oxide 
(III) Lung 
inflammation and 
fibrosis; lung 
cancer
Lung fibrosis, possible 
cancer, and 
mesothelioma
Mode of action Toxic ions reach systemic 
tissues
Toxicity related to 
total deposited or 
retained particle dose 
in target respiratory 
tract region based on 
particle size
Same as PSLT; 
plus reactive 
surface (e.g., 
reactive oxygen 
species)
Durability/
biopersistence
Migration into alveolar 
walls and from lung 
tissue to the pleural
Interference with 
normal cell division
Genotoxicity
Dose metric related to adverse 
effects
Dissolution rate; amount 
absorbed into blood
Surface area
Volume
Mass or number, by 
particle size fraction
Same dose metrics 
as PSLT; plus 
reactivity of 
particle surface
Number of fibers of 
certain dimensions
Total surface area of 
fibers or nanotubes
Dose–response relationship Slope and effect level may 
depend on dissolution
May be nonlinear at 
low doses
Steeper slope and 
lower effect level 
than PSLT
Linear dose–response 
for some endpoints
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Table 2
Basic parameters needed for risk assessment of inhaled particles
Parameter Purpose
Particle size, shape, density Estimate inhalation and lung region-specific deposition fraction
Particle surface area, reactivity, solubility Evaluate mode of action and local or systemic effects
Multiple exposure or dose groups Describe dose–response relationship; estimate benchmark dose
Biological significance of response Evaluate severity and relevance to humans
Body and lung weight; target lung region surface area and volume Normalize dose from animals to humans
J Nanopart Res. Author manuscript; available in PMC 2015 October 24.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Kuempel et al. Page 23
Table 3
Excess risk estimates (0.1 %) of lung cancer associated with airborne particle exposure, based on exposure 
concentration in rat chronic inhalation studies and extrapolated to worker-equivalent concentration
Particle type and sizea,b
Rat airborne exposure concentration (mg/m3)c
Worker-equivalent (8-h TWA) airborne concentration 
(mg/m3)d
MLE 95 % LCL MLE 95 % LCL
TiO2 (fine) 2.0 1.7 3.9 3.3
MoO3 (fine) 1.6 1.1 2.3 1.6
CB (ultrafine) 0.031 0.020 0.14 0.12
DEP (ultrafine) 0.031 0.020 0.13 0.086
CoSO4 (fine) 0.027 0.013 0.065 0.029
NiO (fine) 0.026 0.015 0.034 0.019
Ni3S2 (fine) 0.0081 0.0039 0.010 0.0050
GaAs (fine) 0.0041 0.0027 0.0065 0.0043
Data used in the analyses: TiO2 (fine) (Lee et al. 1985, male and female rats); CB (Nikula et al. 1995, female; Heinrich et al. 1995, female); DEP 
(Nikula et al. 1995, female); MoO3 (male and female), GaAs (female), CoSO4 (male), NiO (female), and Ni3S2 (female) (NTP 1996–2000)
MLE Maximum likelihood estimate; 95 % LCL 95 % Lower confidence limit; DEP Diesel exhaust particulate; CB Carbon black; TWA Time-
weighted average
aAll are respirable, nonfibrous, poorly soluble particles (e.g.,<0.1 g/100 ml in water for NiO, Ni3S2, GaAs; 0.5 g/100 ml for MoO3) (Melnick et 
al. 2003), except CoSO4 which is soluble. Size category refers to primary particle (ultrafine <100 nm)
c
MLE or 95 % LCL estimate based on multistage model (polynomial degree 2) estimate of 10 % excess risk with linear extrapolation to 0.1 % 
excess risk
dAdjusted for rat and human differences in air inhaled per day (~0.24–0.36 m3/24-h based on rat body weight (EPA 1987) and 9.6 m3/8-h day in 
workers (ICRP 1994)), exposure duration (6–18 h/d rat and 8-h/dayhumans), alveolar deposition fraction (estimated in MPPD 2.0 (CIIT and RIVM 
2006) based on airborne particle size reported in animal studies), and alveolar lung surface area (102 m2 human/0.4 m2 rat)
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Table 4
Excess risk estimates (0.1 %) of lung cancer associated with airborne particle exposure based on particle lung 
burden after chronic inhalation exposure in rats and extrapolated to worker-equivalent concentration
Particle type and sizea Rat lung burden (mg/g lung)b Worker-equivalent (8-h TWA) airborne concentration (mg/m3)c
MLE 95 % LCL MLE 95 % LCL
TiO2 (fine) 1.9 1.6 1.6 1.3
DEP (ultrafine) 0.42 0.37 0.26 0.23
TiO2 (ultrafine) 0.20 0.17 0.16 0.14
CB (ultrafine) 0.16 0.11 0.15 0.10
MLE Maximum likelihood estimate; 95 % LCL: 95 % lower confidence limit; DEP Diesel exhaust particulate; CB Carbon black. TWA Time-
weighted average
Data used in the analyses TiO2 (fine) (Lee et al. 1985, male and female); DEP (Nikula et al. 1995, male and female; Heinrich et al. 1995, female); 
CB (Nikula et al. 1995, female; Heinrich et al. 1995, female); TiO2 (ultrafine) Heinrich et al. 1995, female
aAll are nonfibrous, poorly soluble particles. Size category refers to primary particle
b
MLE or 95 % LCL estimates based on multistage model (polynomial degree 2) estimate of 10 % excess risk with linear extrapolation to 0.1 % 
excess risk; except, TiO2 estimates were based on model fit to the particle surface area lung dose of fine and ultrafine TiO2 data combined due to 
insufficient dose groups to model ultrafine TiO2 alone (equivalent mass dose was estimated by means of specific surface area, 48 m2/g ultrafine 
TiO2 and 4.99 m2/g fine TiO2) (NIOSH 2011)
cWorking lifetime exposure concentration associated with human-equivalent lung burden was estimated from the MPPD human lung dosimetry 
model (CIIT and RIVM 2006) by means of the Yeh and Schum deposition model; reference worker breathing parameters equivalent to 9.6 m3/8-h 
day (ICRP 1994; NIOSH 2011) for 2250 week (5 days/week, 50 week/year, for 45 year; airborne particle size and density as reported in animal 
studies; oronasal normal augmenter; and inhalability adjustment)
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Table 5
Comparative potency of carbon nanotubes to other types of particles or fibers associated with noncancer lung 
responses following short-term or subchronic exposure in rats or mice
Comparisona Relative potency factorb Reference
SWCNT/SiO2 2.5 Shvedova et al. (2005)
SWCNT/CB-UF 2.5 Shvedova et al. (2005)
MWCNT/chrysotile asbestos ~1 Muller et al. (2005)
MWCNT/CB-UF 1.5 Muller et al. (2005)
MWCNT/CB-UF 10c Pauluhn (2010)
Elder et al. (2005)
SWCNT Single-walled carbon nanotubes; MWCNT Multi-walled carbon nanotubes; SiO2 Respirable crystalline silica; CB Carbon black; UF 
Ultrafine
aComparisons based on same dose and duration: Shvedova: alveolar interstitial connective tissue thickness (measure of pulmonary fibrosis); dose: 
40 μg per mouse, 28 days (SWCNT and CB-UF), or 60 days (SWCNT and SiO2) after pharyngeal aspiration; Muller: amount of type 1 soluble 
collagen (measure of pulmonary fibrosis); dose: 2 mg per rat, 60 day after intratracheal instillation
b
Potency is the inverse of the critical effect levels; that is, the lower the dose associated with a critical effect, the greater the potency. Thus, potency 
factor is calculated: (dose associated with CNT effect/dose associated with comparison effect)−1
cNo observed adverse effect levels (NOAELs) in rats after subchronic (13-week) to CNT or CB, i.e., [0.1 mg/m3 (Pauluhn 2010); 1 mg/m3 (Elder 
et al. 2005] −1
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